Diversified Trust Co Lowers Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Diversified Trust Co lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 63.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,519 shares of the company’s stock after selling 2,680 shares during the period. Diversified Trust Co’s holdings in IDEXX Laboratories were worth $854,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of IDXX. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the third quarter worth about $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares in the last quarter. Finally, Wormser Freres Gestion raised its stake in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on IDXX shares. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Up 1.5%

Shares of NASDAQ IDXX opened at $549.16 on Thursday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The firm’s 50-day moving average price is $559.95 and its 200-day moving average price is $616.34. The stock has a market capitalization of $43.32 billion, a price-to-earnings ratio of 40.44, a P/E/G ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the business posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.